Buflomedil

Buflomedil
IUPAC name 4-(pyrrolidin-1-yl)-1-(2,4,6-trimethoxyphenyl)butan-1-one
Identifiers
CAS number	55837-25-7 Y
PubChem	2467
ChemSpider	2373 Y
ChEMBL	CHEMBL188921 Y
ATC code	C04AX20
Jmol-3D images	Image 1
SMILES O=C(c1c(OC)cc(OC)cc1OC)CCCN2CCCC2
InChI InChI=1S/C17H25NO4/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18/h11-12H,4-10H2,1-3H3 Y Key: OWYLAEYXIQKAOL-UHFFFAOYSA-N Y InChI=1/C17H25NO4/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18/h11-12H,4-10H2,1-3H3 Key: OWYLAEYXIQKAOL-UHFFFAOYAG
Properties
Molecular formula	C17H25NO4
Molar mass	307.38 g/mol
Y (verify) (what is: Y/N?) Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

Buflomedil is a vasoactive drug used to treat claudication or the symptoms of peripheral arterial disease. It is currently not approved by the FDA for use in the United States. Currently available as trade name tablet Loftyl

Toxicity

This drug might be suspended from marketing in the European Union, because of concerns about severe neurological and cardiac toxicity. In its press release dated 17 November 2011 EMA suggested that doctors "should stop using buflomedil and consider alternative treatment options".

Various adverse effects have been reported to the FDA.